CoChat
Sign Up
Cited by 189CAR-T cell therapy researchVirus-based gene therapy researchImmunotherapy and Immune Responses

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

Open access
Prommersberger, Sabrina, Reiser, Michael, Beckmann, Julia, Danhof, Sophia, Amberger, Maximilian, Quade-Lyssy, Patricia, Einsele, Hermann, Hudecek, Michael, Bonig, Halvard, Ivics, Zoltán·2021·Gene Therapy
DOI 10.1038/s41434-021-00254-wPMC PMC8455317
Open this paper in CoChat — free accountOpen PDF

Abstract

Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A key ambition of the CARAMBA project is to provide clinical proof-of-concept for virus-free CAR gene transfer using advanced Sleeping Beauty (SB) transposon technology. SB transposition in CAR-T engineering is attractive due to the high rate of stable CAR gene transfer enabled by optimized hyperactive SB100X transposase and transposon combinations, encoded by mRNA and minicircle DNA, respectively, as preferred vector embodiments. This approach bears the potential to facilitate and expedite vector procurement, CAR-T manufacturing and distribution, and the promise to provide a safe, effective, and economically sustainable treatment. As an exemplary and novel target for SB-based CAR-T cells, the CARAMBA consortium has selected the SLAMF7 antigen in multiple myeloma. SLAMF7 CAR-T cells confer potent and consistent anti-myeloma activity in preclinical assays in vitro and in vivo. The CARAMBA clinical trial (Phase-I/IIA; EudraCT: 2019-001264-30) investigates the feasibility, safety, and anti-myeloma efficacy of autologous SLAMF7 CAR-T cells. CARAMBA is the first clinical trial with virus-free CAR-T cells in Europe, and the first clinical trial that uses advanced SB technology worldwide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41434-021-00254-w

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CAR-T-cell manufacturing pipeline. Patients undergo leukapheresis in the clinic to extract T cells, which are transported to a GMP facility, where manufacturing takes place. The CAR gene is introduced into the cells’ genome, leading to receptor expression and conversion into a CAR-T cell. CAR-T cells are then expanded in order to reach therapeutically relevant numbers. Finally, product formulation takes place, and the manufactured product is transported back to the clinic to be infused into the patient. CAR composition: antigen binding domain (1), transmembrane domain (2) spanning the cell membrane (3), costimulatory domain (4), and signaling domain (5).
Fig. 1 CAR-T-cell manufacturing pipeline. Patients undergo leukapheresis in the clinic to extract T cells, which are transported to a GMP facility, where manufacturing takes place. The CAR gene is introduced into the cells’ genome, leading to receptor expression and conversion into a CAR-T cell. CAR-T cells are then expanded in order to reach therapeutically relevant numbers. Finally, product formulation takes place, and the manufactured product is transported back to the clinic to be infused into the patient. CAR composition: antigen binding domain (1), transmembrane domain (2) spanning the cell membrane (3), costimulatory domain (4), and signaling domain (5).CC BY · PubMed Central
Fig. 2 Schematic overview of gene delivery with Sleeping Beauty transposition. The SB transposase is introduced into a cell in form of DNA (expression plasmid), mRNA, or recombinant protein along with donor DNA in which the transposon to be mobilized is located. After binding within the terminal inverted repeats of the transposon (TIRs, yellow rectangles) flanking a gene of interest (GOI, green rectangle), SB transposase (blue circles) performs the excision of the transposon from the donor DNA (black strand) and integrates it into a site in the genomic target DNA (purple strand).
Fig. 2 Schematic overview of gene delivery with Sleeping Beauty transposition. The SB transposase is introduced into a cell in form of DNA (expression plasmid), mRNA, or recombinant protein along with donor DNA in which the transposon to be mobilized is located. After binding within the terminal inverted repeats of the transposon (TIRs, yellow rectangles) flanking a gene of interest (GOI, green rectangle), SB transposase (blue circles) performs the excision of the transposon from the donor DNA (black strand) and integrates it into a site in the genomic target DNA (purple strand).CC BY · PubMed Central
Fig. 3 Schematic of the CARAMBA CAR construct and manufacturing process. A Schematic of the transposon construct: an EF1α promoter drives expression (arrow) of the SLAMF7 CAR (modeled after the medicinal antibody elotuzumab) and, by means of a T2A element, the human truncated EGFR (huEGFRt). GMCSFRss: GM-CSF receptor-α chain signal sequences. B Flowchart of CARAMBA IMP manufacturing. Manufacturing steps are (1) apheresis, (2) immunomagnetic selection and CD3/CD28 activation, (3) nucleofection with SB100X transposase mRNA and SLAMF7 CAR-tEGFR transposon, (4) CD3/CD28-bead removal and transfer to G-Rex culture flasks, (5) half-medium change, and (6) harvest and formulation.
Fig. 3 Schematic of the CARAMBA CAR construct and manufacturing process. A Schematic of the transposon construct: an EF1α promoter drives expression (arrow) of the SLAMF7 CAR (modeled after the medicinal antibody elotuzumab) and, by means of a T2A element, the human truncated EGFR (huEGFRt). GMCSFRss: GM-CSF receptor-α chain signal sequences. B Flowchart of CARAMBA IMP manufacturing. Manufacturing steps are (1) apheresis, (2) immunomagnetic selection and CD3/CD28 activation, (3) nucleofection with SB100X transposase mRNA and SLAMF7 CAR-tEGFR transposon, (4) CD3/CD28-bead removal and transfer to G-Rex culture flasks, (5) half-medium change, and (6) harvest and formulation.CC BY · PubMed Central
Fig. 4 Multiple myeloma cells expressing SLAMF7 and targeting them with CAR-T cells. A dSTORM image showing SLAMF7 molecules expressed on MM.1S (ATCC ref. CRL-2974) cells. Cells were stained with anti-SLAMF7 Alexa Fluor 647 antibody. The inset displays a bright field image of the same cells. B Confocal microscope image showing the interaction between a SLAMF7 CAR-T cell and a MM.1S target cell. Cells were stained with phalloidin Atto643 for actin (green), with anti-CAR CF568 antibody (orange) and Hoechst 34580 for nuclei (blue).
Fig. 4 Multiple myeloma cells expressing SLAMF7 and targeting them with CAR-T cells. A dSTORM image showing SLAMF7 molecules expressed on MM.1S (ATCC ref. CRL-2974) cells. Cells were stained with anti-SLAMF7 Alexa Fluor 647 antibody. The inset displays a bright field image of the same cells. B Confocal microscope image showing the interaction between a SLAMF7 CAR-T cell and a MM.1S target cell. Cells were stained with phalloidin Atto643 for actin (green), with anti-CAR CF568 antibody (orange) and Hoechst 34580 for nuclei (blue).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

Sorted by citations

Items 101–189 of 189

Related

See all

Metadata

Authors
Prommersberger, S., Reiser, M., Beckmann, J., Danhof, S., Amberger, M., Quade-Lyssy, P., Einsele, H., Hudecek, M., Bonig, H., & Ivics, Z.
Affiliations
  • Universitätsklinikum Würzburg (DE)
  • Goethe University Frankfurt (DE)
  • Paul Ehrlich Institut (DE)
Corresponding author
Ivics, Zoltán
ORCID
Venue
Gene Therapy
Publisher
Springer Science and Business Media LLC
Published
2021-04-13
Volume
28
Issue
9
Pages
560-571
ISSN
  • 0969-7128 (ISSN-L)
  • 1476-5462
DOI
10.1038/s41434-021-00254-w
PMC
PMC8455317
OpenAlex
W3154860673
Cited by
182
References
62
Citations by year
2026: 23 · 2025: 38 · 2024: 43 · 2023: 35 · 2022: 28 · 2021: 15
FWCI
11.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Gene Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
Funders
EC | Horizon 2020 Framework Programme (754658)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
SLAMF7, chimeric antigen receptor T cells, multiple myeloma, Sleeping Beauty transposon, DNA minicircles
MeSH terms
Signaling Lymphocytic Activation Molecule Family, Humans, Multiple Myeloma, T-Lymphocytes, Genetic Therapy, Immunotherapy, Adoptive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review